First published · Last updated
Effets de l’utilisation d’un inhibiteur du cotransporteur sodium-glucose de type 2 sur les évènements cardiovasculaires indésirables majeurs chez des participants vivant avec un diabète de type 2 et une maladie cardiovasculaire athérosclérotique traites par tirzépatide versus dulaglutide (SURPASS-CVOT)
Journal article (Elsevier BV) reporting on effects of an SGLT2 inhibitor on major adverse cardiovascular events among people with type 2 diabetes and atherosclerotic cardiovascular disease treated with tirzepatide versus dulaglutide; published 2026-09-01. The supplied source fields do not include study results, location, or broader impact details.
Categories: public-health, science-and-space
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 6/10
- Geographic reach
- 1/10
- Global importance
- 3/10
- Impact magnitude
- 3/10
- Positivity
- 5/10
- Urgency
- 1/10
Why it matters
The article addresses cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease, which is directly relevant to clinical and public-health audiences.